One of the key constraints in the MIS-C EAP has been awareness from other practitioners and hospitals in the peds space. MIS-C is rare, and even rarer that someone treating MIs-C is aware of Ryoncil.
in order for the EAP to progress to a trial, it is likely to require more patients.
this publication should help increase its awareness and generate more patients for the EAP.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-40
-
- There are more pages in this discussion • 384 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.030(3.13%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | $1.03 | 96.5¢ | $4.704M | 4.708M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 87395 | 98.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 274051 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |